

Trivalent Inactivated Influenza Vaccine (Inactivated Subunit, Adjuvanted) (TIIV) FLUAD®

Supplier: Seqirus Canada Inc.

INDICATIONS:

- Individuals 65 years of age and older.

The vaccine is not approved for use in those under 65 years of age.

DOSES AND SCHEDULE:

- 1 dose given as 0.5 mL **IM**.
-

ADMINISTRATION:

No additional requirements.

BOOSTER DOSES AND RE-IMMUNIZATION:

Annually.

SEROLOGICAL TESTING:

Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:

1. History of anaphylactic reaction to a previous dose of any type of influenza vaccine or to any component of FLUAD®.
 2. History of Guillain-Barré syndrome (GBS) within 8 weeks of receipt of a previous dose of influenza vaccine without another cause being identified.
 3. Receipt of a CTLA-4 inhibitor (e.g., ipilimumab) alone or in combination with other checkpoint inhibitors for the treatment of cancer. Inactivated influenza vaccine should be given 8 weeks before starting treatment or 8 weeks after the last dose. For more specific details refer to the BC Cancer [Influenza vaccine recommendations](#).
-

PRODUCT COMPONENTS:

Potential allergens: polysorbate 80, ovalbumin, neomycin, kanamycin, hydrocortisone (See SPECIAL CONSIDERATIONS).

Other components: potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, formaldehyde, cetyltrimethylammonium bromide (CTAB), barium, squalene, sorbitan trioleate, sodium citrate, citric acid.

PRECAUTIONS:

Severe oculo-respiratory syndrome (ORS) after a previous dose of influenza vaccine. ^A

^A See [Safety Issues Applicable to Influenza Vaccines, 2. Oculo-Respiratory Syndrome \(ORS\)](#).

**Trivalent Inactivated Influenza Vaccine (Inactivated Subunit, Adjuvanted) (TIIV)
FLUAD®**

Supplier: Seqirus Canada Inc.

SPECIAL CONSIDERATIONS:

Egg allergic individuals (including those who have experienced anaphylaxis following egg ingestion) can be immunized with inactivated or live attenuated influenza vaccine in any setting attended by immunization service providers who are following standard vaccine administration practice. ^A

ADVERSE EVENTS:

Local: pain, warmth, redness. Pain and warmth occur more often than after non-adjuvanted vaccines.

Systemic: headache, fatigue, malaise, myalgia. Fewer than 1 in 20 people may develop oculo-respiratory syndrome (ORS). Symptoms include red eyes, a cough, and/or sore throat and/or hoarseness.

^A See [Safety Issues Applicable to Influenza Vaccines, 1. Egg Allergic Individuals](#).